Global Patent Index - EP 2243494 A1

EP 2243494 A1 20101027 - Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.

Title (en)

Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.

Title (de)

Arzneimittelzusammensetzung, enthaltend einen Steroid-dehydrogenase-reduktase-Hemmer und einen Mineralocorticoidantagonisten.

Title (fr)

Composition pharmaceutique, renfermant un inhibiteur de la steroid-déshydrogénase-reductase et un antagoniste de récepteurs de minéralocorticoide.

Publication

EP 2243494 A1 20101027 (EN)

Application

EP 09005672 A 20090422

Priority

EP 09005672 A 20090422

Abstract (en)

A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.

IPC 8 full level

A61K 45/06 (2006.01)

CPC (source: EP)

A61K 31/192 (2013.01); A61K 31/222 (2013.01); A61K 31/575 (2013.01); A61K 31/585 (2013.01); A61K 45/06 (2013.01)

Citation (applicant)

  • TD PALLIN, EXPERT OPIN. THER. PATENTS, vol. 17, no. 12, 2007, pages 1407 - 1422
  • KA HUGHES; SP WEBSTER; BR WALKER, EXPERT OPIN. INVEST. DRUGS, vol. 17, no. 4, 2008, pages 481 - 496
  • WILKINSON-BERKA JL ET AL.: "Identification of a Retinal Aldosterone System and the Protective Effects of Mineralocorticoid Receptor Antagonism on Retinal Vascular Pathology", CIRC. RES., vol. 104, no. 1, 2009, pages 124 - 133
  • RICKARD A; YOUNG M: "Corticosteroid receptors, macrophages and cardiovascular disease", J. MOL. ENDOCRINOL., vol. 08, 2009, pages 0144
  • OSMOND JM; DORRANCE AM.: "11{beta}HSD2 Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size Following Cerebral Ischemia", ENDOCRINOLOGY, 2008
  • ODERMATT A; GUMY C: "Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals", BIOCHEM PHARMACOL, vol. 76, no. 10, 2008, pages 1184 - 93
  • MOLNAR GA ET AL., GLUCOCORTICOID-RELATED SIGNALING EFFECTS IN VASCULAR SMOOTH MUSCLE CELLS. HYPERTENSION, vol. 51, no. 5, 2008, pages 1372 - 1378
  • GUO C ET AL.: "Mineralocorticoid Receptor Blockade Reverses Obesity-Related Changes in Expression of Adiponectin, Peroxisome Proliferator-Activated Receptor-{gamma}, and Proinflammatory Adipokines", CIRCULATION, vol. 117, no. 17, 2008, pages 2253 - 2261
  • WALKER BR.: "Glucocorticoids and Cardiovascular Disease", EUR. J. ENDOCRINOL., vol. 157, no. 5, 2007, pages 545 - 8
  • CLARK AR: "Anti-inflammatory functions of glucocorticoid-induced genes", MOL CELL ENDOCRINOL, vol. 275, no. 1-2, 2007, pages 79 - 97
  • CAPRIO M ET AL.: "Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis", FASEB J, vol. 21, no. 9, 2007, pages 2185 - 2194
  • HULTMAN ML ET AL.: "The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms", MOL. ENDOCRINOL., vol. 19, no. 6, 2005, pages 1460 - 1473
  • CHROUSOS GP; KINO T.: "Intracellular Glucocorticoid Signaling: A Formerly Simple System Turns Stochastic.", SCIENCE'S STKE, vol. 304, 2005, pages PE48
  • WALKER EA; STEWART PM: "11 beta-hydroxysteroid dehydrogenase: unexpected connections", TRENDS ENDOCRINOL METAB, vol. 14, no. 7, 2003, pages 334 - 9

Citation (search report)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA RS

DOCDB simple family (publication)

EP 2243494 A1 20101027; WO 2010121814 A1 20101028

DOCDB simple family (application)

EP 09005672 A 20090422; EP 2010002477 W 20100422